Literature DB >> 19690981

Mutational analysis of CDKN2A gene in a group of 390 larynx cancer patients.

Katarzyna Kiwerska1, Małgorzata Rydzanicz, Andrzej Kram, Martyna Pastok, Agata Antkowiak, Wenancjusz Domagała, Krzysztof Szyfter.   

Abstract

CDKN2A gene belongs to the genes involved in cell cycle regulation. When is absent or inactivated by mutation or promoter hypermethylation a cell may undertake an uncontrolled proliferation. Inactivation of CDKN2A gene is observed in many human malignancies, including larynx cancer. In this study we investigated mutations in exon 1 and exon 2 of CDKN2A gene in a large group of 390 laryngeal cancers. We found 40 different alterations (17%) and nearly half of them was not described previously. Out of these alterations two transversions in codon 108: c.322G>C (Asp108His) and c.322G>T (Asp108Tyr) as well as a G>A transition in codon 110 (Trp110X) were found more frequently (altogether: 7 cases in codon 108 and 10 cases in codon 110). This result, concerning the location of these codons in the ankyrin repeat structures, may suggest that these two codons may be critical hot-spots in larynx carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19690981     DOI: 10.1007/s11033-009-9731-z

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  55 in total

1.  A minimum folding unit in the ankyrin repeat protein p16(INK4).

Authors:  B Zhang; Z y Peng
Journal:  J Mol Biol       Date:  2000-06-16       Impact factor: 5.469

2.  Gene promoter hypermethylation in tumors and serum of head and neck cancer patients.

Authors:  M Sanchez-Cespedes; M Esteller; L Wu; H Nawroz-Danish; G H Yoo; W M Koch; J Jen; J G Herman; D Sidransky
Journal:  Cancer Res       Date:  2000-02-15       Impact factor: 12.701

Review 3.  p16(MTS-1/CDKN2/INK4a) in cancer progression.

Authors:  J W Rocco; D Sidransky
Journal:  Exp Cell Res       Date:  2001-03-10       Impact factor: 3.905

4.  Biallelic deletions in INK4 in cutaneous melanoma are common and associated with decreased survival.

Authors:  Eva Grafström; Suzanne Egyházi; Ulrik Ringborg; Johan Hansson; Anton Platz
Journal:  Clin Cancer Res       Date:  2005-04-15       Impact factor: 12.531

5.  Karyotypic heterogeneity and clonal evolution in squamous cell carcinomas of the head and neck.

Authors:  Charlotte Jin; Yuesheng Jin; Johan Wennerberg; Jan Akervall; Michael Dictor; Fredrik Mertens
Journal:  Cancer Genet Cytogenet       Date:  2002-01-15

6.  Comparison of p16(INK4a) expression with p53 alterations in head and neck cancer by tissue microarray analysis.

Authors:  S Karsai; U Abel; M Roesch-Ely; A Affolter; C Hofele; S Joos; P K Plinkert; F X Bosch
Journal:  J Pathol       Date:  2007-02       Impact factor: 7.996

7.  p16MTS1/CDK4I mutations and concomitant loss of heterozygosity at 9p21-23 are frequent events in squamous cell carcinoma of the larynx.

Authors:  P Jares; P L Fernández; A Nadal; M Cazorla; L Hernández; M Pinyol; S Hernández; J Traserra; A Cardesa; E Campo
Journal:  Oncogene       Date:  1997-09-18       Impact factor: 9.867

8.  DNA methylation markers and early recurrence in stage I lung cancer.

Authors:  Malcolm V Brock; Craig M Hooker; Emi Ota-Machida; Yu Han; Mingzhou Guo; Stephen Ames; Sabine Glöckner; Steven Piantadosi; Edward Gabrielson; Genevieve Pridham; Kristen Pelosky; Steven A Belinsky; Stephen C Yang; Stephen B Baylin; James G Herman
Journal:  N Engl J Med       Date:  2008-03-13       Impact factor: 91.245

9.  Loss of heterozygosity and mutation analysis of the p16 (9p21) and p53 (17p13) genes in squamous cell carcinoma of the head and neck.

Authors:  M V González; M F Pello; C López-Larrea; C Suárez; M J Menéndez; E Coto
Journal:  Clin Cancer Res       Date:  1995-09       Impact factor: 12.531

10.  Tumor suppressor p16INK4A: determination of solution structure and analyses of its interaction with cyclin-dependent kinase 4.

Authors:  I J Byeon; J Li; K Ericson; T L Selby; A Tevelev; H J Kim; P O'Maille; M D Tsai
Journal:  Mol Cell       Date:  1998-02       Impact factor: 17.970

View more
  4 in total

1.  Mutational Status of CDKN2A and TP53 Genes in Laryngeal Squamous Cell Carcinoma.

Authors:  Teodora A Todorova; Stanislav H Jordanov; Gergana S Stancheva; Ivan J Chalakov; Mincho B Melnicharov; Kuncho V Kunev; Vanio I Mitev; Radka P Kaneva; Teodora E Goranova
Journal:  Pathol Oncol Res       Date:  2014-08-23       Impact factor: 3.201

2.  CDKN2A Germline Rare Coding Variants and Risk of Pancreatic Cancer in Minority Populations.

Authors:  Robert R McWilliams; Eric D Wieben; Kari G Chaffee; Samuel O Antwi; Leon Raskin; Olufunmilayo I Olopade; Donghui Li; W Edward Highsmith; Gerardo Colon-Otero; Lauren G Khanna; Jennifer B Permuth; Janet E Olson; Harold Frucht; Jeanine Genkinger; Wei Zheng; William J Blot; Lang Wu; Luciana L Almada; Martin E Fernandez-Zapico; Hugues Sicotte; Katrina S Pedersen; Gloria M Petersen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-07-23       Impact factor: 4.254

3.  Methylation of tumor suppressor genes in ovarian cancer.

Authors:  Filiz Ozdemir; Julide Altinisik; Ates Karateke; Hakan Coksuer; Nur Buyru
Journal:  Exp Ther Med       Date:  2012-09-18       Impact factor: 2.447

4.  Significance of CDKN2A gene A148T variant in patients with bladder cancer.

Authors:  Edyta Borkowska; Adam Jędrzejczyk; Andrzej Kruk; Michał Pietrusiński; Magdalena Traczyk; Marek Rożniecki; Bogdan Kałużewski
Journal:  Cent European J Urol       Date:  2011-09-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.